Medicare AdvantageCoverageMedium impact
Foot Bath Medications (Revised)
Humana·Pharmacy, Dermatology·Medicare Advantage
Effective date
Jan 1, 2021
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its Foot Bath Medications policy (effective 1/1/2021, revised 5/28/2025) to require that foot bath/soak medications meet label or compendia-supported indications to be considered medically necessary. Claims for common foot bath medications (budesonide, ciclopirox, clindamycin phosphate, fluocinonide, ketoconazole, linezolid, nystatin, vancomycin) dispensed without approved compendia support will be rejected with error code 88 (NCPDP) or 527 (internal) and require clinical pharmacy review for coverage determination.
Action Required
Immediately: Billing team must implement system edits to flag all prescriptions for foot bath medications (budesonide, ciclopirox, clindamycin phosphate, fluocinonide, ketoconazole, linezolid, nystatin, vancomycin) when claimed for foot bath/soak use on Humana Medicare Advantage plans. Before dispensing or billing, verify with clinical pharmacy that the indication has label or approved compendia support; claims lacking this support will be rejected (NCPDP error 88, internal error 527) and require Humana clinical review. Update pharmacy staff and prescriber communications to clarify that foot bath compounds must have documented medically accepted indications (MAIs) per CMS Part D guidelines. If compendia support cannot be verified, do not bill; contact Humana prior authorization line at www.humana.com/PAL for guidance. Failure to comply will result in claim denials and potential compliance issues with CMS Part D requirements.